Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
Article Details
- CitationCopy to clipboard
Paton DM
Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
Drugs Today (Barc). 2017 Feb;53(2):89-102. doi: 10.1358/dot.2017.53.2.2589164.
- PubMed ID
- 28387387 [ View in PubMed]
- Abstract
Deutetrabenazine is a derivative of tetrabenazine in which two trideuteromethoxy groups substitute two methoxy groups. The active metabolites of deutetrabenazine have a longer half-life than those of tetrabenazine, together with a greater overall absorption. However, the peak plasma concentrations are lower. Because of these pharmacokinetic differences, deutetrabenazine can be given twice daily, thus improving compliance. The lower peak concentrations may account for a lower incidence of some unwanted adverse effects. Unlike tetrabenazine, deutetrabenazine has no effect on the QT interval. Treatment with deutetrabenazine significantly improved chorea in Huntington's disease, the hyperkinetic features of tardive dyskinesia, and tics in Tourette syndrome. In all three conditions, deutetrabenazine produced an acceptable level of overall adverse effects without causing any severe adverse effects.
DrugBank Data that Cites this Article
- Drugs
- Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareDeutetrabenazineMoricizine The risk or severity of adverse effects can be increased when Moricizine is combined with Deutetrabenazine. DeutetrabenazineAlimemazine The risk or severity of adverse effects can be increased when Alimemazine is combined with Deutetrabenazine. DeutetrabenazineLithium cation The risk or severity of adverse effects can be increased when Lithium cation is combined with Deutetrabenazine. DeutetrabenazineOsanetant The risk or severity of adverse effects can be increased when Osanetant is combined with Deutetrabenazine. DeutetrabenazineBifeprunox The risk or severity of adverse effects can be increased when Bifeprunox is combined with Deutetrabenazine.